Stock WVE WAVE LIFE SCIENCES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
5.81 USD -3.17% Intraday chart for Wave Life Sciences Ltd. -5.99% +15.05%
May. 15 Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target MT
May. 09 Transcript : Wave Life Sciences Ltd., Q1 2024 Earnings Call, May 09, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
GL
Wave Life Sciences : Improving the Potency and Sequence Versatility of RNA Editing Through Oligonucleotide Chemical Modifications
PU
Wave Life Sciences : Impact of Phosphoryl Guanidine (PN) Variants on siRNA Potency and Durability in Hepatic and Extrahepatic Tissues
PU
First clinical evidence for myocyte stem (satellite) cell targeting in DMD: Results from Part A of a Phase 1b/2 study of WVE-N531
PU
A Phase 1b/2 Open label Study of WVE N531 in Patients with Duchenne Muscular Dystrophy: Part B (FORWARD 53) Study Design and Rationale
PU
Wave Life Sciences : Potent, Durable mRNA Knockdown in Extrahepatic Tissues Using siRNAs With Novel Phosphoryl Guanidine Backbone Variants
PU
Wave Life Sciences : Chemical Design of Oligonucleotides That Support Targeted RNA Editing in the CNS of Non-Human Primates
PU
Wave Life Sciences: Q1 Earnings Snapshot
AQ
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
GL
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
GL
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
GL
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
GL
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
GL
Wave Life Sciences to Present at Upcoming Investor Conferences
GL
Wave Life Sciences: Q4 Earnings Snapshot
AQ
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
GL
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
GL
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. WVE Stock
  4. News Wave Life Sciences Ltd.
  5. Press Releases